as 11-11-2025 2:05pm EST
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | ACTON |
| Market Cap: | 3.9M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 103.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -19.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.26 - $10.20 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 55.56% |
BJDX Breaking Stock News: Dive into BJDX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
MT Newswires
a month ago
MT Newswires
a month ago
MT Newswires
a month ago
GlobeNewswire
a month ago
MT Newswires
5 months ago
The information presented on this page, "BJDX Bluejay Diagnostics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.